Barrons : AI Is Fueling Mergers. Here Are 2 That Make Sense.



From: Laurent Chekroun (MAKOR CAPITAL MARKET) At: 07/05/25 13:17:36 UTC+2:00
Subject: Barrons : AI Is Fueling Mergers. Here Are 2 That Make Sense.
AI Is Fueling Mergers. Here Are 2 That Make Sense.

When Hewlett Packard Enterprise got government approval to close its acquisition of Juniper Networks this past weekend, the stock soared. More often an acquirer’s stock falls on deal news. But the age of artificial intelligence is changing the equation.

For HPE, the fit is particularly good. Juniper, a networking equipment firm, puts it in a much better spot to compete against Cisco Systems and Nvidia in the market for the high-speed networking equipment that is required in AI data centers.

HPE shares rose 12.6% on Monday, making it the top performing stock in the S&P 500 on the day. The deal officially closed on Wednesday.

Success breeds imitation, and there may be other legacy tech companies looking to the merger market to improve their AI position. I’m not an investment banker, but here are some deals I wouldn’t be surprised to see—and that could get a good reception from the market.

Oracle and C3.ai: Oracle is a prime candidate to add AI to its software through an acquisition.

Oracle has already begun transforming itself for the AI age. With perfect timing in 2020, Oracle began running the Microsoft playbook: Transform from a legacy software maker into a cloud company. It has been moving customers to cloud-based versions of its software with annual subscriptions, while at the same time building large data centers to rent out cloud servers for AI and traditional workloads. In fiscal 2025, revenue from the cloud was up 24%, while the rest of Oracle was flat on the year.

Ironically for a software company, Oracle’s AI play to date has largely been in hardware: AI cloud servers. It could use an AI software merger that, grafted on to existing Oracle offerings, would leverage the mountains of proprietary data customers have in Oracle databases.

Enter C3.ai. C3’s offerings would fit nicely on top of Oracle’s software. C3 has 130 ready-made AI applications tailored for different industries, solving problems and helping to predict outcomes. Today, its customers are clustered in energy, manufacturing, government, and the military.

C3’s revenue grew by 25% to $389 million in fiscal 2025, but it posted a $289 million loss. The culprits were sky-high expenses, 183% of revenue. But in a merger, sales and administrative expenses, which together represented 86% of revenue, would be trimmed heavily once integrated into Oracle’s large sales force and bureaucracy.

After a sharp selloff this year, C3 has a $4.2 billion market capitalization. Oracle could use its $11 billion in cash, or its stock, which trades at a premium to its historical price/earnings ratio for the next 12 months. Paying with cash could hamper Oracle’s plans for data center investment, coming in at $21.2 billion last year, tripled from the year before, and future plans may require more debt, now at $109 billion. In the end, competing capital requirements may be the largest hurdle for this merger.

An Oracle/ C3.ai merger would face one obstacle right off the bat. The company’s founders have a history. C3 CEO Tom Siebel was among Oracle’s early employees, and became a top salesperson. In the early 1990s, Larry Ellison, Oracle’s chairman, rejected Siebel’s idea for a new product. Siebel left Oracle and took his idea to form Siebel Systems, which became successful.

As Siebel’s software got traction, a long war of words emerged between the two. In the end, Ellison and Siebel made up enough to agree to an acquisition, with Oracle paying $5.85 billion for Siebel Systems in 2005. Another deal would make sense.

Check Point Software and SentinelOne. Check Point Software Technologies is a pioneer in cybersecurity. Its software builds a wall around corporate networks, but increasingly, workers are doing things outside those walls, like working from home or using cloud applications. Check Point also has a cloud-security product that is mature and integrated with its network security.

SentinelOne’s strength is AI-driven “endpoint security,” proactively protecting employee devices no matter what network they are connected to. Check Point has its own endpoint solution, but SentinelOne’s is a more popular product.

Check Point grew revenue by 6% last year, a much slower pace than 20 years ago, but it also generates a lot of free cash flow, which has largely gone to share repurchases. Check Point has reduced its share count by 55% since 2005, becoming a classic “value” play. Now it could turn back to growth.

SentinelOne is a much younger company, growing smartly. Revenue rose by 32% last fiscal year, but, like C3.ai, it took a huge loss, with total expenses at 140% of revenue. Some 82% of its revenue went to sales and administrative costs, the kind of expenses that would be greatly reduced after a merger, also thanks to Check Point’s larger scale and existing sales force.

SentinelOne has a market capitalization of $6.8 billion, and the stock is down 12% over the past year, versus a gain of 12.5% for S&P 500.

The bet here is that a combined offering covering network, cloud, and endpoint security would allow Check Point to upsell its existing base of over 100,000 customers. Check Point had just $1.5 billion in cash and short-term investments at the end of March. The deal could be all-stock, or Check Point, which has no debt, could borrow to finance the purchase.

As with any deal, integration is expensive, so shareholders would need to be patient. It could be worth the wait.

>>> US Research Calls I

Research Calls I
  • Upgrades
    • Alliant Energy (LNT) upgraded to Outperform from Peer Perform at Wolfe Research, tgt $68
    • Autodesk (ADSK) upgraded to Buy from Neutral at DA Davidson, tgt $375
    • CACI (CACI) upgraded to Outperform from Market Perform at William Blair
    • Constellation Brands (STZ) upgraded to Buy from Hold at Jefferies, tgt $205
    • Equity Residential (EQR) upgraded to Outperform from In Line at Evercore ISI, tgt $75
    • Phibro Animal Health (PAHC) upgraded to Overweight from Neutral at JPMorgan, tgt $35
    • PSEG (PEG) upgraded to Buy from Neutral at UBS, tgt $97
    • POSCO (PKX) upgraded to Overweight from Equal Weight at Morgan Stanley
    • RenaissanceRe (RNR) upgraded to Equal Weight from Underweight at Barclays, tgt $256
    • Sunrun (RUN) upgraded to Outperform from Neutral at BNP Paribas Exane, tgt $21
    • Shoals Technologies (SHLS) upgraded to Buy from Hold at Jefferies, tgt $7.20
    • T-Mobile (TMUS) upgraded to Neutral from Sell at Rothschild & Co Redburn, tgt $228
    • UDR (UDR) upgraded to Outperform from In Line at Evercore ISI, tgt $46
    • U.S. Bancorp (USB) upgraded to Strong Buy from Outperform at Raymond James, tgt $57
  • Downgrades
    • Applied Materials (AMAT) downgraded to Neutral from Buy at Rothschild & Co Redburn, tgt $200
    • ASGN (ASGN) downgraded to Underperform from Hold at Jefferies, tgt $42
    • BAE Systems (BAESY) downgraded to Reduce from Hold at Kepler Cheuvreux
    • Chubb (CB) downgraded to Equal Weight from Overweight at Barclays, tgt $298
    • CrowdStrike (CRWD) downgraded to Neutral from Overweight at Piper Sandler
    • Essent Group (ESNT) downgraded to Market Perform from Outperform at Keefe Bruyette, tgt $67
    • MP Materials (MP) downgraded to Hold from Buy at Jefferies, tgt $33
    • Netflix (NFLX) downgraded to Neutral from Buy at Seaport Research, tgt $1,400
    • NMI Holdings (NMIH) downgraded to Market Perform from Outperform at Keefe Bruyette, tgt $43
    • Olo (OLO) downgraded to Sector Perform from Outperform at RBC Capital, tgt $10.25
    • Progressive (PGR) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $290
    • SK Telecom (SKM) downgraded to Sell from Neutral at Goldman
    • Stellantis (STLA) downgraded to Neutral from Buy at BofA Securities, tgt $11.75
    • Sun Life Financial (SLF) downgraded to Underweight from Equal Weight at Barclays
    • Tesla (TSLA) downgraded to Market Perform from Outperform at William Blair
    • Travelers (TRV) downgraded to Equal Weight from Overweight at Barclays, tgt $274
    • Wells Fargo (WFC) downgraded to Market Perform from Strong Buy at Raymond James
  • Others
    • AbCellera (ABCL) assumed with an Outperform at Leerink, tgt $5
    • Aethlon Medical (AEMD) assumed with a Neutral at H.C. Wainwright, tgt $1.50
    • Alaska Air (ALK) assumed with a Neutral at UBS, tgt $49
    • Allegiant Travel (ALGT) assumed with a Neutral at UBS, tgt $59
    • Ategrity Specialty Insurance Company (ASIC) initiated with a Neutral at Citigroup, tgt $26
    • Ategrity Specialty Insurance Company (ASIC) initiated with an Overweight at Wells Fargo, tgt $29
    • Ategrity Specialty Insurance Company (ASIC) initiated with an Overweight at Barclays, tgt $30
    • Ategrity Specialty Insurance Company (ASIC) initiated with an Overweight at JPMorgan, tgt $26
    • Ategrity Specialty Insurance Company (ASIC) initiated with a Buy at TD Cowen; tgt $27
    • AT&T (T) reinstated with a Buy at BofA Securities, tgt $32
    • Benitec Biopharma (BNTC) initiated with a Buy at TD Cowen
    • Bioventus (BVS) initiated with an Overweight at Cantor Fitzgerald, tgt $12
    • Caesars (CZR) initiated with a Buy at Goldman, tgt $36
    • Chime (CHYM) initiated with an Outperform at Evercore ISI, tgt $38
    • Chime (CHYM) initiated with a Hold at Deutsche Bank; tgt $35
    • Chime (CHYM) initiated with a Buy at Canaccord, tgt $40
    • Chime (CHYM) initiated with an Outperform at William Blair
    • Chime (CHYM) initiated with an Overweight at Barclays, tgt $40
    • Chime (CHYM) initiated with an Outperform at Wolfe Research, tgt $38
    • Chime (CHYM) initiated with an Overweight at Piper Sandler, tgt $40
    • Chime (CHYM) initiated with a Neutral at UBS, tgt $35
    • Chime (CHYM) initiated with an Overweight at JPMorgan, tgt $40
    • Chime (CHYM) initiated with an Overweight at Morgan Stanley, tgt $39
    • Chime (CHYM) initiated with a Neutral at Goldman, tgt $34
    • CNX Resources (CNX) initiated with an Equal Weight at Barclays, tgt $33
    • Energy Transfer LP (ET) initiated with a Buy at TD Cowen, tgt $22
    • Enterprise Products (EPD) initiated with a Hold at TD Cowen, tgt $33
    • EQT Corporation (EQT) initiated with an Overweight at Barclays, tgt $65
    • Frontier Group (ULCC) assumed with a Neutral at UBS, tgt $4
    • GE Vernova (GEV) initiated with a Buy at UBS, tgt $614
    • JetBlue (JBLU) assumed with a Sell at UBS, tgt $3
    • Kinder Morgan (KMI) initiated with a Buy at TD Cowen, tgt $34
    • LendingClub (LC) initiated with a Market Perform at Citizens JMP
    • Las Vegas Sands (LVS) initiated with a Neutral at Goldman, tgt $52
    • MGM Resorts (MGM) initiated with a Sell at Goldman, tgt $34
    • Monopar Therapeutics (MNPR) initiated with an Overweight at Cantor Fitzgerald, tgt $74
    • Okta (OKTA) initiated with a Sell at Arete, tgt $83
    • ONEOK (OKE) initiated with a Hold at TD Cowen, tgt $91
    • Rockwell Automation (ROK) initiated with an Outperform at CICC, tgt $381
    • Rhythm Pharmaceuticals (RYTM) initiated with an Outperform at Leerink, tgt $88
    • SailPoint (SAIL) initiated with a Sell at Arete, tgt $16
    • SanDisk (SNDK) initiated with a Buy at Jefferies
    • T-Mobile (TMUS) reinstated with a Neutral at BofA Securities, tgt $255
    • Targa Resources (TRGP) initiated with a Hold at TD Securities, tgt $192
    • Verizon (VZ) reinstated with a Neutral at BofA Securities, tgt $45
    • Voyager Technologies (VOYG) initiated with a Buy at BofA Securities, tgt $50
    • Voyager Technologies (VOYG) initiated with an Overweight at JPMorgan, tgt $52
    • Voyager Technologies (VOYG) initiated with an Equal Weight at Morgan Stanley, tgt $46
    • Voyager Technologies (VOYG) initiated with an Outperform at Wolfe Research; tgt $50
    • Voyager Technologies (VOYG) initiated with an Equal Weight at Barclays, tgt $45
    • Voyager Technologies (VOYG) initiated with an Overweight at KeyBanc
    • Voyager Technologies (VOYG) initiated with a Buy at Jefferies, tgt $50
    • Williams (WMB) initiated with a Buy at TD Cowen, tgt $67
    • Wynn Resorts (WYNN) initiated with a Buy at Goldman, tgt $122

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • SHEL -2.9% (provides Q2 production update; sees Q2 upstream production of 1,660 - 1,760 kboe/d; provides adjusted EBITDA guidance metrics).
Other news:
  • SOL -1% ( announces north america management change and preliminary Q2 2025 operating results ).
  • NRIX -1.6% (announces that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma).
  • MAG -2% (reminds shareholders to vote "for" the arrangement with Pan American Silver (PAAS)).
  • UMC -2.3% (reports June 2025 sales +7.3% yr/yr to $18.8 bln).
  • FFAI -2.6% (Founder and Co-CEO, YT Jia, shares weekly investor update).
  • DEFT -3.8% (provides monthly AUM update).
  • TSLA -6.5% ( CEO Elon Musk creates "America Party", TSLA seeing increased competition in China, according to WSJ according to WSJ ).
  • BULL -9.3% ( announces $1 billion standby equity agreement; co intends on opportunistically using capital for key growth initiatives ).
  • NWTN -9.4% (announces Mr. Adrian Wong as Chief Financial Officer and Mr. John Xie as Chief Operating Officer; Both appointments effective July 3, 2025 ).
  • QSI -9.8% (announces pricing of $50 million registered direct offering of common stock ).
  • JSPR -73.4% (Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria ).

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • MOH +2.3% ( sees Q2 EPS below consensus; lowers FY25 guidance).
M&A news:
  • WNS +14.1% (Capgemini to acquire WNS for $76.50/share).
Other news:
  • APGE +18.7% (announces positive 16-week data from phase 2 APEX clinical trial of APG777, its potentially best-in-class Anti-IL-13 antibody, in moderate-to-severe atopic dermatitis ).
  • COGT +18.7% (announces "positive" top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis demonstrating clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden).
  • KALV +12.9% (announces FDA approval of EKTERLY, first and only oral on-demand treatment for hereditary angioedema).
  • SAND +9.6% (enters into definitive agreement with Royal Gold Inc. (RGLD) in which Royal Gold will acquire SAND in an all-share transaction with an implied value of approximately $3.5 bln ).
  • IREN +4.5% (publishes its monthly update for June 2025).
  • LXEO +4.5% (announces that the U.S. Food and Drug administration has granted Breakthrough Therapy designation to LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich ataxia)
  • RKLB +3.9% (Barron's out positive on RKLB).
  • AEMD +3.2% ( Hemopurifier to Enhance Anti-PD1 Therapy; Assuming Coverage With Neutral Rating and $1.50 PT -- H.C. Wainwright).
  • LGIH +2.8% (announced it closed 457 homes in June 2025 and closed 1,323 homes in the second quarter of 2025).
  • DNLI +2.1% (FDA accepts BLA for review seeking accelerated approval for tividenofusp alfa for Hunter syndrome ).
  • AZN +1% ( Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer).
  • OGN +1% (announces that VTAMA cream, 1%, was granted a strong recommendation by the American Academy of Dermatology in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis).

WSJ : Saudi Fund Invests Hundreds of Millions in Proposed NYC Skyscraper

Saudi Fund Invests Hundreds of Millions in Proposed NYC Skyscraper
The Kingdom’s Public Investment Fund is teaming with New York developer Related Cos.

  • Saudi Arabia’s Public Investment Fund is taking a two-thirds stake in the site of a planned Manhattan skyscraper project with Related Cos.
  • The project, potentially an office building, reflects foreign investors returning to New York’s recovering real-estate market.
  • PIF’s investment highlights its growing global property portfolio beyond Saudi megaprojects.

Saudi Arabia’s government fund is taking a two-thirds stake in a site for a planned Manhattan skyscraper, the latest sign that foreign investors are flocking back to New York’s rapidly recovering real-estate market.

The Kingdom’s Public Investment Fund is teaming with Related Cos., which has said it is planning to build a 1,200 foot tower on the site. The New York developer and the Saudis own this site one block from Central Park, which was purchased last year for more than $600 million.

Related initially planned a mixed-use project there with residential, retail and a hotel. But more recently the firm said it has been considering an office building instead to take advantage of the strong demand among businesses for top-quality space in the city.

The overall cost for the site and development is expected to be more than $1 billion, according to people familiar with the matter. The Saudi fund’s final contribution is still being determined, but PIF has already invested about $200 million, these people said.

Foreign investors this year have been returning to New York City’s commercial-property market, which is the largest, most liquid and one of the top performers in the U.S.

U.S. property developments and investments slowed considerably early on during the pandemic. They were hit again after interest rates soared in 2022, pushing down values. Foreign investor interest evaporated.

But lately investment in New York has been recovering as more workers return to the office, providing a new lift for neighboring businesses. Manhattan’s office leasing during the first half of the year surpassed the same period in some years before Covid-19’s outbreak, according to data firm CoStar Group.

New York City apartment rents are at all-time highs—boosting the mayoral candidacy of democratic socialist Zohran Mamdani, who recently won the Democratic primary while pledging a rent freeze. The city’s visitor numbers are just below record highs.

Eastdil Secured has seen the increase in foreign activity first hand. The real-estate brokerage and investment bank has $12 billion worth of New York real-estate deals completed or under way in 2025, according to Chief Executive Roy March.

“Virtually every one of them has some level of foreign capital involved,” he said.

Foreign investors purchased over $2.1 billion of Manhattan commercial property in the first quarter of 2025 and the last quarter of 2024 combined, according to data firm MSCI. That total was five times as much as the same six-month period two years earlier.

The Saudi Public Investment Fund has assets of about $1 trillion, making it one of the world’s largest investors. It is one of the major overseas funds returning to New York.

The fund has a close relationship with Related, best known for its sprawling Hudson Yards development on Manhattan’s west side. In 2020, the Saudi fund made a debt investment in Related that is convertible into a 15% equity stake. Since then the two have consulted closely on numerous real-estate projects.

Saudi’s Public Investment Fund has historically been a relatively small player in real estate outside of Saudi Arabia—instead directing its property-focused dollars toward domestic megaprojects meant to transform the country.

But in the past few years, it has planted its flag on a number of high-profile global properties and brands. Last year it took a 40% stake in Selfridges, a high-end U.K. department-store group that boasts a grand flagship by London’s Hyde Park.

In 2022, it joined with other funds to put $900 million into the ultraluxury hotelier Aman, and in 2023 bought a 49% stake in the upmarket hotel chain Rocco Forte.

>>> Congress passes and President Trump signs “One Big Beautiful Bill.” The bill

Congress passes and President Trump signs “One Big Beautiful Bill.” The bill includes extension of 2017 tax cuts, spending cuts (Medicaid and green energy spending), deregulation, energy reform, immigration reform, and a debt ceiling increase of $5 trillion (625.34)
  • The bill extends 2017 tax cuts for all income levels with an increased standard deduction. Tax cuts will be made permanent.
  • The bill eliminates taxes on tips and overtime through 2028 with some income limits.
  • The bill increases deductions for seniors on Social Security by $4000.
  • The bill makes permanent write-offs for business interest expenses and R&D.
  • The bill provides $170 billion for border security, construction of a border wall, and deportations.
  • The bill requires most solar and wind projects to be placed in service by 2027 to qualify for tax credits, with some carveouts for projects that get started by July of 2026 (the excise tax on solar & wind projects was removed from the bill).
  • Nuclear power credits will last until 2036. Hydrogen tax credits will be phased out in 2028.
  • EV tax credits will end in September of 2025.
  • The bill starts Medicaid work requirements beginning in December of 2026. The Medicaid provider tax will drop to 3.5% by 2028.
  • The bill creates a $50 billion fund for rural hospitals.
  • The bill makes auto loan interest tax deductible.
  • The bill will limit gambling loss write-offs for recreational gamblers to 90% of winnings for that tax year (previous deduction was allowed at 100% of winnings).
  • The bill raises the debt ceiling by $5 trillion.
  • The bill raises the state and local tax deduction to $40,000 for people making $500K or less. SALT cap will go back to $10K after 5 years.
  • The bill makes changes to the IRS free tax filing program, pending review by a task force.
  • The bill includes tax on college endowments and private foundations.
  • The bill requires states to share the cost of some SNAP benefits.
  • The bill limits how much students can borrow from the government for college.
  • The bill includes reforms for how pharmacy benefit managers do business with the government.
  • The bill creates a new savings account for children, and $1000 of funding will be provided.
  • The bill provides new tax credits for nuclear energy.
  • The bill will provide billions for the construction of the "Golden Dome" missile defense shield.
  • The bill raises the child tax credit to $2200 from $2000.
  • The bill provides additional money for air traffic control and some other defense programs.
  • The bill provides additional tax credits for semiconductor companies that build capacity in the U.S.

Full Bill Text

Deficit Impact:
The CBO said that the Senate bill will add $3.3 trillion to deficits over the next 10 years. The CBO "estimates that enacting the substitute amendment would increase by 11.8 million the number of people without health insurance in 2034. That amount includes an estimated 1.4 million people without verified citizenship, nationality, or satisfactory immigration status who would no longer be covered in state-only funded programs in 2034."
Related stocks: TAN, FSLR, SPWR, CSIQ, SUN, NEE, GEV, CWEN, CHPT, EVGO, BLNK, TSLA, RIVN, F, GM, STLA, HMC, TM, FSR, LCID, CXW, GEO, UNH, HUM, CNC, CVS, ALHC, MOH, CI, ELV, THC, UHS, CYH, HCA, HRB, INTU, SAH, CVNA, AN, PAG, GPI, NLR, CCJ, URA, CAE, GD, LMT, NOC, LHX, LIN, APD, PLUG, BE, TOL, LEN, DHI, NVR, CZR, MGM, WYNN, LVS, DKNG, FLUT, PENN, DG, DLTR, FIVE, WMT, SOFI, SLM, SMH, AMD, INTC, AVGO, TSM, AVGO

>>> Europe : Brokers Upgrades & Downgrades - 7th of July 2025 V3(++)

>>> Up
* Allianz PT Raised to 431 euros from 419 euros at Berenberg
* Berkeley Raised to Buy at Peel Hunt
* Bilfinger PT Raised to 100 euros at Bankhaus Metzler
* Constellation Brands Raised to Buy at Jefferies; PT $205 (++)
* Generali Raised to Overweight at JPMorgan; PT 37 euros
* Nordea Bank Raised to Hold at Kepler Cheuvreux (+)
* Norwegian Air Raised to Hold at ABG; PT 14 kroner
* Nvidia PT Raised to $190 from $180 at Citi (+)
* ProSieben Raised to Overweight at JPMorgan; PT 11 euros
* Schindler PT Raised to 330 Swiss francs at Bank Vontobel (+)
* T-Mobile Raised to Neutral at Rothschild & Co Redburn

>>> Down
* Aixtron Cut to Hold at Kepler Cheuvreux; PT 17 euros (++)
* Applied Materials Cut to Neutral at Rothschild & Co Redburn (+)
* Atrium Ljungberg Cut to Hold at Kepler Cheuvreux (+)
* Currys Cut to Sector Perform at RBC
* Duell Cut to Reduce at Inderes; PT 4.80 euros
* Embla Medical HF Cut to Hold at ABG; PT 35 kroner
* Inter Cars Cut to Neutral at Citi; PT 645 zloty
* Kion Cut to Hold at mwb research AG; PT 46 euros (++)
* Merck KGaA Cut to Sell at Stifel; PT 100 euros
* Netflix Cut to Neutral at Seaport Global Securities
* Netflix Cut to Neutral at President Capital Management (+)
* Pandora Cut to Hold at HSBC; PT 1,250 kroner
* Pop. Sondrio Cut to Reduce at Equita; PT 9.90 euros (+)
* Poste Italiane Cut to Neutral at JPMorgan; PT 20 euros
* Stellantis Cut to Neutral at BofA (+)
* Tesla Cut to Market Perform at William Blair (++)
* Wacker Chemie Cut to Hold at DZ Bank; PT 70 euros (++)

>>> Initiation
* Angle Rated New Buy at Singer Capital Markets; PT 17 pence (++)
* Allfunds Rated New Buy at Deutsche Bank; PT 8.50 euros (+)
* Aurubis Rated New Hold at Baptista Research; PT 99.10 euros
* BCP Rated New Neutral at Citi; PT 70 euro cents
* Boku Rated New Buy at Canaccord; PT 271 pence (+)
* Cheniere Energy Rated New Buy at Mirae Asset Securities; PT $290
* Dassault Systemes ADRs Rated New Underperform at BNPP Exane (++)
* Faron Pharma Rated New Buy at Bryan Garnier; PT 371.31 pence (+)
* Inmobiliaria Colonial Resumed Buy at Citi
* Poste Italiane Rated New Outperform at Baptista Research
* Prysmian Rated New Hold at Baptista Research; PT 68.30 euros
* Remy Cointreau Reinstated Neutral at BNPP Exane; PT 42 euros (++)
* Rockwell Automation Rated New Outperform at CICC; PT $381
* Rosebank Rated New Buy at Stifel; PT 420 pence (+)
* Skinbiotherapeutics Rated New Buy at Singer Capital Markets (++)
* Snam Rated New Hold at Baptista Research; PT 5.50 euros
* Tenaris Rated New Hold at Baptista Research; PT 18.20 euros
* Voyager Technologies Rated New Buy at Jefferies; PT $50
* Wacker Chemie Rated New Buy at Baptista Research; PT 91.20 euros

>>> Call
* Penmaker BIC’s Shares Fall After UBS Analyst Cuts Estimates, PT (++)
* Currys Downgraded at RBC, Valuation Fair and Macro Outlook Mixed
* Deutsche Bank Strategists Say Equity Exposure Nearing Neutral (+)
* Generali Raised, While Poste Italiane Downgraded at JPMorgan
* JPMorgan’s Matejka Sees European Stocks Consolidating Further (+)
* Merck KGaA Double Downgraded at Stifel on Patent Expiry Risk (+)
* MGM Rated Sell at Goldman on Vegas Pressures; Caesars Rated Buy (++)
* Pandora Drops as HSBC Downgrades; Price Target and Estimates Cut (++)
* Shell Slides After RBC Says Weak Update Breaks Positive Streak (+)
* Stellantis Cut to Neutral at BofA on Fears of ‘Very Weak’ 1H (+)
* Vidrala Maintained Outperform at Grupo Santander (++)
* Weir Seems Primed for a Re-Rating, Citi Upgrades Shares to Buy

>>> Europe : Brokers Upgrades & Downgrades - 7th of July 2025 V2(+)

>>> Up
* Allianz PT Raised to 431 euros from 419 euros at Berenberg
* Berkeley Raised to Buy at Peel Hunt
* Bilfinger PT Raised to 100 euros at Bankhaus Metzler
* Generali Raised to Overweight at JPMorgan; PT 37 euros
* Nordea Bank Raised to Hold at Kepler Cheuvreux (+)
* Norwegian Air Raised to Hold at ABG; PT 14 kroner
* Nvidia PT Raised to $190 from $180 at Citi (+)
* ProSieben Raised to Overweight at JPMorgan; PT 11 euros
* Schindler PT Raised to 330 Swiss francs at Bank Vontobel (+)
* T-Mobile Raised to Neutral at Rothschild & Co Redburn

>>> Down
* Applied Materials Cut to Neutral at Rothschild & Co Redburn (+)
* Atrium Ljungberg Cut to Hold at Kepler Cheuvreux (+)
* Currys Cut to Sector Perform at RBC
* Duell Cut to Reduce at Inderes; PT 4.80 euros
* Embla Medical HF Cut to Hold at ABG; PT 35 kroner
* Inter Cars Cut to Neutral at Citi; PT 645 zloty
* Merck KGaA Cut to Sell at Stifel; PT 100 euros
* Netflix Cut to Neutral at Seaport Global Securities
* Netflix Cut to Neutral at President Capital Management (+)
* Pandora Cut to Hold at HSBC; PT 1,250 kroner
* Pop. Sondrio Cut to Reduce at Equita; PT 9.90 euros (+)
* Poste Italiane Cut to Neutral at JPMorgan; PT 20 euros
* Stellantis Cut to Neutral at BofA (+)
* Vidrala Cut to Neutral at Grupo Santander; PT 109.11 euros (+)

>>> Initiation
* Allfunds Rated New Buy at Deutsche Bank; PT 8.50 euros (+)
* Aurubis Rated New Hold at Baptista Research; PT 99.10 euros
* BCP Rated New Neutral at Citi; PT 70 euro cents
* Boku Rated New Buy at Canaccord; PT 271 pence (+)
* Cheniere Energy Rated New Buy at Mirae Asset Securities; PT $290
* Faron Pharma Rated New Buy at Bryan Garnier; PT 371.31 pence (+)
* Inmobiliaria Colonial Resumed Buy at Citi
* Poste Italiane Rated New Outperform at Baptista Research
* Prysmian Rated New Hold at Baptista Research; PT 68.30 euros
* Rockwell Automation Rated New Outperform at CICC; PT $381
* Rosebank Rated New Buy at Stifel; PT 420 pence (+)
* Snam Rated New Hold at Baptista Research; PT 5.50 euros
* Tenaris Rated New Hold at Baptista Research; PT 18.20 euros
* Voyager Technologies Rated New Buy at Jefferies; PT $50
* Wacker Chemie Rated New Buy at Baptista Research; PT 91.20 euros

>>> Call
* Currys Downgraded at RBC, Valuation Fair and Macro Outlook Mixed
* Deutsche Bank Strategists Say Equity Exposure Nearing Neutral (+)
* Generali Raised, While Poste Italiane Downgraded at JPMorgan
* JPMorgan’s Matejka Sees European Stocks Consolidating Further (+)
* Merck KGaA Double Downgraded at Stifel on Patent Expiry Risk (+)
* Shell Slides After RBC Says Weak Update Breaks Positive Streak (+)
* Stellantis Cut to Neutral at BofA on Fears of ‘Very Weak’ 1H (+)
* Weir Seems Primed for a Re-Rating, Citi Upgrades Shares to Buy